

# Lynne A Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7293581/publications.pdf>

Version: 2024-02-01

38  
papers

1,554  
citations

279798

23  
h-index

330143

37  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of 5-ethynyl-2-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. <i>Brain Research</i> , 2010, 1319, 21-32.	2.2	172
2	Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. <i>Molecular Cancer</i> , 2007, 6, 48.	19.2	118
3	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5041-5046.	2.2	116
4	Fluorine-18-Labeled Benzamide Analogues for Imaging the $\sigma_2$ Receptor Status of Solid Tumors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3194-3204.	6.4	102
5	Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. <i>Nature Communications</i> , 2017, 8, 14152.	12.8	91
6	Carbon-11 labeled $\sigma_2$ receptor ligands for imaging breast cancer. <i>Nuclear Medicine and Biology</i> , 2005, 32, 423-430.	0.6	67
7	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1700-1707.	3.0	64
8	[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. <i>European Journal of Pharmacology</i> , 2005, 525, 8-17.	3.5	60
9	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1666-1673.	3.0	55
10	MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. <i>Nuclear Medicine and Biology</i> , 2002, 29, 783-790.	0.6	54
11	Synthesis and in Vitro and in Vivo Evaluation of <sup>18</sup> F-Labeled Positron Emission Tomography (PET) Ligands for Imaging the Vesicular Acetylcholine Transporter. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1358-1369.	6.4	48
12	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2010, 37, 509-516.	0.6	48
13	Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. <i>PLoS ONE</i> , 2013, 8, e74188.	2.5	41
14	New N-substituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as $\sigma_2$ receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1222-1231.	3.0	40
15	Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2009, 36, 651-658.	0.6	40
16	Endogenous dopamine (DA) competes with the binding of a radiolabeled D <sub>3</sub> receptor partial agonist in vivo: A positron emission tomography study. <i>Synapse</i> , 2011, 65, 724-732.	1.2	39
17	Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. <i>Molecular Imaging</i> , 2011, 10, 7290.2011.00009.	1.4	37
18	[ <sup>3</sup> H]4-(dimethylamino)N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide: A selective radioligand for dopamine D <sub>3</sub> receptors. II. Quantitative analysis of dopamine D <sub>3</sub> and D <sub>2</sub> receptor density ratio in the caudate-putamen. <i>Synapse</i> , 2010, 64, 449-459.	1.2	34

#	ARTICLE	IF	CITATIONS
19	Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents. <i>International Journal of Pharmacognosy</i> , 1995, 33, 102-122.	0.2	32
20	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€œEXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.8	32
21	Radiosynthesis and biological evaluation of a promising $\gamma$ -receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. <i>Applied Radiation and Isotopes</i> , 2010, 68, 2268-2273.	1.5	28
22	[ <sup>3</sup> H]4-(Dimethylamino)-N-(4-(2-methoxyphenyl)piperazin-1-yl)butyl]benzamide, a selective radioligand for dopamine D <sub>3</sub> receptors. I. In vitro characterization. <i>Synapse</i> , 2009, 63, 717-728.	1.2	27
23	Click Synthesis and Biologic Evaluation of (R)- and (S)-2-Amino-3-[1-(2- <sup>18</sup> F)Fluoroethyl]-1-H-[1,2,3-Triazol-4-yl]Propanoic Acid for Brain Tumor Imaging with Positron Emission Tomography. <i>Molecular Imaging</i> , 2010, 9, 7290.2010.00025.	1.4	27
24	Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. <i>Nuclear Medicine and Biology</i> , 2012, 39, 137-144.	0.6	22
25	Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. <i>Molecular Imaging</i> , 2011, 10, 420-33.	1.4	22
26	Comparison of animal models for the evaluation of radiolabeled androgens. <i>Nuclear Medicine and Biology</i> , 2001, 28, 613-626.	0.6	19
27	Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2648-2654.	3.0	19
28	Synthesis and evaluation of a bromine-76-labeled PPAR $\beta$ antagonist 2-bromo-5-nitro-N-phenylbenzamide. <i>Nuclear Medicine and Biology</i> , 2006, 33, 847-854.	0.6	17
29	Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. <i>Nuclear Medicine and Biology</i> , 2011, 38, 725-739.	0.6	14
30	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	3.1	14
31	Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). <i>Investigational New Drugs</i> , 1997, 15, 187-194.	2.6	12
32	Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist. <i>NeuroImage</i> , 2013, 71, 168-174.	4.2	10
33	Development of $^{18}$ F-Labeled PET Probes for Imaging Cell Proliferation. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 892-908.	2.1	10
34	Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues. <i>Expert Opinion on Investigational Drugs</i> , 1994, 3, 1281-1292.	4.1	7
35	Effect of administration route on FES uptake into MCF-7 tumors. <i>Nuclear Medicine and Biology</i> , 2001, 28, 397-399.	0.6	7
36	Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [ <sup>11</sup> C]CS1P1. <i>Molecular Imaging and Biology</i> , 2020, 22, 285-292.	2.6	5

#	ARTICLE	IF	CITATIONS
37	The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology, 2017, 234, 2019-2030.	3.1	4
38	Fluselenamyl: Evaluation of radiation dosimetry in mice and pharmacokinetics in brains of non-human primate. Nuclear Medicine and Biology, 2020, 82-83, 33-40.	0.6	0